Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582326 | 0.78 | MEN1 (0.52) | MAPTSMN1; SMN2HTTKDM4EMEN1 | |
| SCHEMBL3577903 | 0.77 | NOTUM (0.49) | MAPTSMN1; SMN2HTTKDM4EMEN1 | |
| SCHEMBL3581625 | 0.76 | MEN1 (0.46) | JAK2MAPTIGF1RSMN1; SMN2HTT | |
| SCHEMBL3579704 | 0.75 | RHOA (0.47) | MAPTSMN1; SMN2HTTKDM4EMEN1 | |
| SCHEMBL3584379 | 0.73 | ABCG2 (0.46) | SMN1; SMN2HTTKDM4EMEN1LMNA | |
| SCHEMBL3579042 | 0.73 | ABL1 (0.46) | MAPTSMN1; SMN2HTTKDM4EMEN1 | |
| SCHEMBL3577228 | 0.71 | ALDH1A1 (0.52) | MAPTSMN1; SMN2KDM4ELMNAKMT2A | |
| SCHEMBL24921154 | 0.70 | KDM4E (0.46) | MAPTSMN1; SMN2KDM4EMEN1MAPK1 | |
| SCHEMBL27932708 | 0.70 | NOTUM (0.49) | MAPTKDM4EMAPK1CYP1A2CYP2C9 | |
| SCHEMBL31517450 | 0.70 | KDM4E (0.46) | MAPTSMN1; SMN2KDM4EMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | claimed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | claimed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | claimed |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | disclosed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA3, KCNQ1 | FLT3 1982/4885AURKA 853/4885JAK2 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.